Here we investigated the effects of BET bromodomain inhibition in KRAS-mutated NSCLC and identified the transcriptional changes that conferred sensitivity or led to resensitization using combination approaches with pro-apoptotic agents. The gene discussed is DNER; the disease is non-small cell lung carcinoma.